ISSAR Pharma

The illustration of stomach and large intestine is on the woman's body against gray background. Acid reflux. Female anatomy

ISSAR’s IS-217 for Inflammatory Bowel Diseases

Inflammatory Bowel Diseases (IBD) currently affect approximately 0.5% of the Western world’s population. The globally occurring cases increased from 3.7 million to over 6.8 million between the years 1990 to 2017.

The global IBD market was valued at $210.5 billion in the year 2020 and the growth is estimated to continue for the next few years with several pharmaceutical and bioscience companies increasing investments to build and expand the IBD drug pipeline.

Biologics and IBD market

The market is driven by advanced research and technology for IBD treatment. Different classes of treatments can be used in the treatment of IBD, although biological therapies are gaining more attention as they have greater potential for improved treatment outcomes. Biologics account for 64.9% of the world’s IBD drug market.

Who are the prominent players in the IBD drug pipeline?

Some leading players in the IBD market include Janssen, Pfizer, Genentech, and AbbVie with 5 drugs in all phases (I-III), 5 drugs in phases I and II and 3 drugs in phases II, II/III and III respectively. Most of these drugs are biologics with anti-inflammatory effects inhibiting the inflammatory cytokines IL-12, IL-22, IL-23.

As of 2019 there are a total of 730 global clinical trials taking place, with 63 trials in phase I, 132 trials in phase II, 101 trials in phase III and the remaining in phase IV and pre-clinical stages.

Can ISSAR soon reach patients with their potentially safe, effective and unique anti-inflammatory molecule for IBD?

ISSAR’s 217- An anti-inflammatory molecule for IBD

Issar has developed a novel non-biologic, the non-steroidal, synthetic, small peptide of 10 amino acids, for angiogenesis-related diseases and inflammatory disorders. This novel peptide drug targets the VEGFR-2 which is the major receptor for angiogenesis function.

 It targets VEGFR-2 by down-regulating p38 kinases and IL-23 and IL-17 secretion.

Issar’s IS-217, has successfully proven its potential to arrest angiogenesis and reduce inflammatory cytokine levels in preclinical studies. Issar’s preclinical studies have shown that IS-217 alone is a highly effective agent for IBD.